PDE10 report

Background and objectives

The head of Global Scientific Business Intelligence requested Lifescience Dynamics to carry out six to ten situation analyses on a yearly basis. They needed our help because of constraints on their internal resources and because the substantial syndicated information services they were purchasing neither covered all therapy areas nor were tailored to any specific needs the company required.

An analysis they requested was to write a report on PDE10A and its application in CNS indications. PDE10A is a newly discovered cyclic phosphodiesterase whose function either in health and disease is not known.

It is expressed at high levels in the striatal and adjoining regions of the brain, where the splice variant PDE10A2 appears to predominate. Its distribution in other tissues is unclear but there is some evidence of expression in the testis.

The aim of this study is to review scientific and commercial activity in the PDE10A field and to assess the therapeutic potential of this target, particularly its inhibitors. A separate, complementary study on drugs under development for schizophrenia was also delivered.

Approach

Secondary data were obtained from a wide variety of sources including research papers identified from Medline literature searches; IDdb and pharmaprojects databases, brokers' reports, company, professional association and patient websites. The views of a leading PDE expert were also obtained.

Results delivered

A detailed report of about 100 pages on the PDE10 family and PDA10A subfamily was delivered to the client.